Multiple Sclerosis Drugs Market: By Administration (Oral, Parenteral), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), BY Drug Class (Disease Modifying Drugs (DMDs), Steroids, Others), and Geography  

Purchase Option

$ 4400
$ 6600
$ 8900

Multiple Sclerosis Drugs Market size was valued at USD 23.43 billion in 2022 and is poised to grow at a CAGR of 4.0% over the forecast period 2023-29.  Multiple sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system, particularly the brain and spinal cord. There is currently no cure for MS, but several disease-modifying therapies (DMTs) and symptomatic treatments are available to manage the condition and improve the quality of life for individuals with Multiple Sclerosis. Physically, individuals with Multiple Sclerosis often grapple with debilitating fatigue, which can affect daily activities and overall quality of life. Mobility issues, such as difficulties with walking, balance, coordination, and muscle weakness, are common. The Multiple Sclerosis drug market is experiencing growth driven by several factors. One of the key drivers is the unmet need for drugs to treat Multiple Sclerosis (MS). With extensive research and development (R&D) pipelines, pharmaceutical companies are actively working on new treatments for the disease. MS is a prevalent condition, with approximately 2.3 million people affected globally. Notably, a significant portion of Multiple Sclerosis cases remains undiagnosed in certain parts of the world due to a lack of healthcare infrastructure and limited awareness about the disease. Advancements in biomedical science are creating profitable opportunities for Multiple Sclerosis drug manufacturers in the near future. However, the market also faces challenges, including the patent expiry of key drugs, which can impact market dynamics. Additionally, regulatory requirements and procedures have been strengthening, presenting obstacles to steady market growth. The global Multiple Sclerosis drugs market is notably influenced by the increasing number of patients with secondary progressive relapsing-remitting multiple sclerosis. Efforts by organizations like the National Multiple Sclerosis Society and the Multiple Sclerosis Association of America (MSAA) have played a significant role in raising awareness about the disease and its associated symptoms, contributing to better identification and diagnosis. Overall, the Multiple Sclerosis drug market exhibits both promising growth prospects and challenges, shaped by factors such as the disease's prevalence, evolving R&D efforts, patent issues, and regulatory considerations.

Global Multiple Sclerosis Drugs Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

4%

Largest Market

North America

Fastest Growing Market

Asia Pacific
Multiple Sclerosis Drugs Market Dynamics

The global multiple sclerosis drugs market is majorly influenced by increased number of patients from secondary progressive relapsing-remitting multiple sclerosis. The awareness in identifying multiple sclerosis disease conditions increased because of organizations such as National MS society and Multiple Sclerosis Association of America (MSAA) are actively involved in educating the people regarding associated symptoms and increasing the awareness.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Global Multiple Sclerosis Drugs Market Segmentation

By Administration
  • Oral
  • Parenteral
Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
Drug Class
  • Disease Modifying Drugs (DMDs)
  • Steroids
  • Others

Frequently Asked Questions

Multiple Sclerosis Drugs Market size was valued at USD 23.43 billion in 2022 and is poised to grow at a CAGR of 4.0% over the forecast period 2023-29.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

  1. Executive summary
  2. Global Multiple Sclerosis Drugs Market Introduction
    • Global Multiple Sclerosis Drugs Market - Taxonomy
    • Global Multiple Sclerosis Drugs Market -Definitions
      • Drug Class
      • Distribution Channel
  1. Global Multiple Sclerosis Drugs Market Dynamics
    • Drivers
    • Restraints
    • Opportunities/Unmet Needs of the Market
    • Trends
    • Global Multiple Sclerosis Drugs Market Dynamics - Factors Impact Analysis
    • Global Multiple Sclerosis Drugs Market - Regulations
      • US
      • Europe
      • Japan
    • Global Multiple Sclerosis Drugs Market - Recent Product Launches
  2. Global Multiple Sclerosis Drugs Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029
    • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
    • Year-over-Year (Y-o-Y) Growth Analysis (%)
    • Market Oppurtunity Analysis
  3. Global Multiple Sclerosis Drugs Market, By Drug Class, 2018 - 2022 and Forecast, 2023 - 2029
    • Disease Modifying Drugs (DMDs)
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Steroids
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Others
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Multiple Sclerosis Drugs Market, By Route of Administration, 2018 - 2022 and Forecast, 2023 - 2029
    • Oral
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Parenteral
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Multiple Sclerosis Drugs Market Forecast, By Distribution Channel, 2018 - 2022 and Forecast, 2023 - 2029
    • Hospital Pharmacies
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Retail Pharmacies
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Online Pharmacies
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Multiple Sclerosis Drugs Market Forecast, By Region, 2018 - 2022 and Forecast, 2023 - 2029
    • North America
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Europe
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Asia-Pacific
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Latin America
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Middle East and Africa
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Global Multiple Sclerosis Drugs Market - Opportunity Analysis Index - By Drug Class, By Route of Administration, By Distribution Channel, and Region, 2023 - 2029
  2. North America Multiple Sclerosis Drugs Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029
    • Drug Class Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Disease Modifying Drugs (DMDs)
      • Steroids
      • Others
    • Route of Administration Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Parenteral
    • Distribution Channel Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Retail Pharmacies
      • Hospital Pharmacies
      • Online Pharmacies
    • Country Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • US
      • Canada
    • North America Multiple Sclerosis Drugs Market - Opportunity Analysis Index - By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2023 - 2029
    • North America Multiple Sclerosis Drugs Market Dynamics - Trends
  3. Europe Multiple Sclerosis Drugs Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029
    • Drug Class Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Disease Modifying Drugs (DMDs)
      • Steroids
      • Others
    • Route of Administration Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Parenteral
    • Distribution Channel Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Retail Pharmacies
      • Hospital Pharmacies
      • Online Pharmacies
    • Country Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Germany
      • UK
      • France
      • Spain
      • Italy
      • Russia
      • Poland
      • Rest of Europe
    • Europe Multiple Sclerosis Drugs Market - Opportunity Analysis Index - By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2023 - 2029
    • Europe Multiple Sclerosis Drugs Market Dynamics - Trends
  4. Asia-Pacific Multiple Sclerosis Drugs Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029
    • Drug Class Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Disease Modifying Drugs (DMDs)
      • Steroids
      • Others
    • Route of Administration Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Parenteral
    • Distribution Channel Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Retail Pharmacies
      • Hospital Pharmacies
      • Online Pharmacies
    • Country Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn),
  5. Y-o-Y Growth (%), and Market Share (%)
    • Japan
    • China
    • India
    • ASEAN
    • Australia & New Zealand
    • Rest of Asia-Pacific
  • Asia-Pacific Multiple Sclerosis Drugs Market - Opportunity Analysis Index - By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2023 - 2029
  • Asia-Pacific Multiple Sclerosis Drugs Market Dynamics - Trends
  1. Latin America Multiple Sclerosis Drugs Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029
    • Drug Class Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Disease Modifying Drugs (DMDs)
      • Steroids
      • Others
    • Route of Administration Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Parenteral
    • Distribution Channel Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Retail Pharmacies
      • Hospital Pharmacies
      • Online Pharmacies
    • Country Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Brazil
      • Mexico
      • Argentina
      • Venezuela
      • Rest of Latin America
    • Latin America Multiple Sclerosis Drugs Market - Opportunity Analysis Index - By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2023 - 2029
    • Latin America Multiple Sclerosis Drugs Market Dynamics - Trends
  2. Middle East & Africa Multiple Sclerosis Drugs Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029
    • Drug Class Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Disease Modifying Drugs (DMDs)
      • Steroids
      • Others
    • Route of Administration Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Parenteral
    • Distribution Channel Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Retail Pharmacies
      • Hospital Pharmacies
      • Online Pharmacies
    • Country Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Gulf Cooperation Council (GCC) Countries
      • Israel
      • South Africa
      • Rest of MEA
    • MEA Multiple Sclerosis Drugs Market - Opportunity Analysis Index - By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2023 - 2029
    • MEA Multiple Sclerosis Drugs Market Dynamics - Trends
  3. Competition Landscape
    • Strategic Dashboard of Top Market Players
    • Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
      • Novartis AG (Switzerland)
      • Teva Pharmaceutical industries Ltd. (Israel)
      • Biogen, Inc. (U.S.)
      • Merck & Co., Inc. (U.S.)
      • Sanofi S.A. (France)
      • Acorda Therapeuitics (U.S.)
      • Pfizer Inc. (U.S.)
      • Bayer AG (Germany)
      • Medtronic plc (Questcor Pharmaceuiticals) (U.S.)
  1. Research Methodology
  2. Key Assumptions and Acronyms
  • Novartis AG (Switzerland)
  • Teva Pharmaceutical industries Ltd. (Israel)
  • Biogen, Inc. (U.S.)
  • Merck & Co., Inc. (U.S.)
  • Sanofi (France)
  • Acorda Therapeuitics (U.S.)
  • Pfizer Inc. (U.S.)
  • Bayer AG (Germany)
  • Medtronic plc (Questcor Pharmaceuiticals) (U.S.)

Adjacent Markets